Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Accounts Payables (2021 - 2026)

Zentalis Pharmaceuticals has reported Accounts Payables over the past 6 years, most recently at $7.4 million for Q1 2026.

  • For Q1 2026, Accounts Payables fell 5.03% year-over-year to $7.4 million; the TTM value through Mar 2026 reached $7.4 million, down 5.03%, while the annual FY2025 figure was $7.2 million, 3.09% down from the prior year.
  • Accounts Payables for Q1 2026 was $7.4 million at Zentalis Pharmaceuticals, up from $7.2 million in the prior quarter.
  • Over five years, Accounts Payables peaked at $20.4 million in Q2 2024 and troughed at $3.7 million in Q2 2025.
  • A 5-year average of $10.6 million and a median of $10.5 million in 2024 define the central range for Accounts Payables.
  • Biggest five-year swings in Accounts Payables: skyrocketed 66.11% in 2024 and later crashed 81.81% in 2025.
  • Year by year, Accounts Payables stood at $11.2 million in 2022, then skyrocketed by 32.71% to $14.9 million in 2023, then crashed by 50.17% to $7.4 million in 2024, then decreased by 3.09% to $7.2 million in 2025, then rose by 2.36% to $7.4 million in 2026.
  • Business Quant data shows Accounts Payables for ZNTL at $7.4 million in Q1 2026, $7.2 million in Q4 2025, and $7.0 million in Q3 2025.